AR083208A1 - Uso de estearato de magnesio en formulaciones de polvo seco para inhalacion - Google Patents
Uso de estearato de magnesio en formulaciones de polvo seco para inhalacionInfo
- Publication number
- AR083208A1 AR083208A1 ARP110103586A ARP110103586A AR083208A1 AR 083208 A1 AR083208 A1 AR 083208A1 AR P110103586 A ARP110103586 A AR P110103586A AR P110103586 A ARP110103586 A AR P110103586A AR 083208 A1 AR083208 A1 AR 083208A1
- Authority
- AR
- Argentina
- Prior art keywords
- inhalation
- dry powder
- powder formulations
- magnesium estearate
- hydrolysis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5015—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5089—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Otolaryngology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Uso de estearato de magnesio en formulación en polvo para inhalación que comprende partículas de vehículo para inhibir o reducir la degradación química de un ingrediente activo que porta un grupo susceptible de hidrólisis. Una formulación farmacéutica en forma de polvo seco para inhalación que comprende (a) un vehículo, (b) estearato de magnesio, y c) una sustancia ingrediente activo susceptible de hidrólisis.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10183018 | 2010-09-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR083208A1 true AR083208A1 (es) | 2013-02-06 |
Family
ID=43618674
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP110103586A AR083208A1 (es) | 2010-09-30 | 2011-09-29 | Uso de estearato de magnesio en formulaciones de polvo seco para inhalacion |
Country Status (13)
Country | Link |
---|---|
US (3) | US20120082727A1 (es) |
EP (1) | EP2621494B1 (es) |
KR (2) | KR20140005150A (es) |
CN (1) | CN103298470B (es) |
AR (1) | AR083208A1 (es) |
BR (1) | BR112013007022B1 (es) |
CA (1) | CA2813096C (es) |
ES (1) | ES2704688T3 (es) |
HK (1) | HK1187822A1 (es) |
PL (1) | PL2621494T3 (es) |
RU (1) | RU2580890C2 (es) |
TR (1) | TR201901644T4 (es) |
WO (1) | WO2012041717A1 (es) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9925282B2 (en) | 2009-01-29 | 2018-03-27 | The General Hospital Corporation | Cromolyn derivatives and related methods of imaging and treatment |
GB0918249D0 (en) | 2009-10-19 | 2009-12-02 | Respivert Ltd | Compounds |
CA2794941C (en) | 2010-04-01 | 2018-05-15 | Chiesi Farmaceutici S.P.A. | Process for preparing carrier particles for dry powders for inhalation |
UY33337A (es) | 2010-10-18 | 2011-10-31 | Respivert Ltd | DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS |
NZ627963A (en) | 2012-03-13 | 2015-08-28 | Respivert Ltd | Dry powder pharmaceutical formulations for inhalation of a compound that inhibits pi3 kinase |
JP6267685B2 (ja) | 2012-04-13 | 2018-01-24 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited | 集合粒子 |
EP3563849A3 (en) | 2012-10-25 | 2020-02-12 | The General Hospital Corporation | Combination therapies for the treatment of alzheimer's disease and related disorders |
US10058530B2 (en) | 2012-10-25 | 2018-08-28 | The General Hospital Corporation | Combination therapies for the treatment of Alzheimer's disease and related disorders |
WO2014106727A1 (en) * | 2013-01-03 | 2014-07-10 | Vectura Limited | Inhaler and formulation |
GB201305825D0 (en) * | 2013-03-28 | 2013-05-15 | Vectura Ltd | New use |
US10525005B2 (en) | 2013-05-23 | 2020-01-07 | The General Hospital Corporation | Cromolyn compositions and methods thereof |
CA2928028A1 (en) | 2013-10-22 | 2015-04-30 | The General Hospital Corporation | Cromolyn derivatives and related methods of imaging and treatment |
CN116889562A (zh) | 2016-08-31 | 2023-10-17 | 通用医疗公司 | 与神经退行性疾病相关的神经炎症中的巨噬细胞/小胶质细胞 |
AU2017423862A1 (en) | 2017-07-20 | 2020-02-06 | Aztherapies, Inc. | Powdered formulations of cromolyn sodium and ibuprofen |
AU2019299347A1 (en) | 2018-07-02 | 2021-01-21 | Aztherapies, Inc. | Powdered formulations of cromolyn sodium and alpha-lactose |
WO2023224577A1 (en) * | 2022-05-18 | 2023-11-23 | Arven Ilac Sanayi Ve Ticaret Anonim Sirketi | Inhalation compositions comprising micronized human insulin |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT1283036E (pt) | 1998-11-13 | 2008-03-06 | Jagotec Ag | Inalador de pó seco de dose múltipla com um reservatório de pó |
WO2000053157A1 (en) | 1999-03-05 | 2000-09-14 | Chiesi Farmaceutici S.P.A. | Improved powdery pharmaceutical compositions for inhalation |
PE20011227A1 (es) | 2000-04-17 | 2002-01-07 | Chiesi Farma Spa | Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros |
SI1386630T1 (sl) | 2002-07-31 | 2006-10-31 | Chiesi Farma Spa | Inhalator za prasek |
US20060147389A1 (en) * | 2004-04-14 | 2006-07-06 | Vectura Ltd. | Devices and pharmaceutical compositions for enhancing dosing efficiency |
JP2009513529A (ja) | 2003-07-11 | 2009-04-02 | グラクソ グループ リミテッド | ステアリン酸マグネシウムを含む医薬製剤 |
GB0613161D0 (en) * | 2006-06-30 | 2006-08-09 | Novartis Ag | Organic Compounds |
GB0714134D0 (en) * | 2007-07-19 | 2007-08-29 | Norton Healthcare Ltd | Dry-powder medicament |
US7590021B2 (en) | 2007-07-26 | 2009-09-15 | Qualcomm Incorporated | System and method to reduce dynamic RAM power consumption via the use of valid data indicators |
EP2022783A1 (en) | 2007-08-08 | 2009-02-11 | CHIESI FARMACEUTICI S.p.A. | "Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors" |
EP2154136A1 (en) * | 2008-08-08 | 2010-02-17 | CHIESI FARMACEUTICI S.p.A. | Quinuclidine carbonate derivatives and medicinal compositions thereof |
-
2011
- 2011-09-16 WO PCT/EP2011/066062 patent/WO2012041717A1/en active Application Filing
- 2011-09-16 CN CN201180047864.3A patent/CN103298470B/zh active Active
- 2011-09-16 CA CA2813096A patent/CA2813096C/en active Active
- 2011-09-16 KR KR1020137007256A patent/KR20140005150A/ko not_active Application Discontinuation
- 2011-09-16 TR TR2019/01644T patent/TR201901644T4/tr unknown
- 2011-09-16 EP EP11767661.9A patent/EP2621494B1/en active Active
- 2011-09-16 PL PL11767661T patent/PL2621494T3/pl unknown
- 2011-09-16 KR KR1020177027944A patent/KR101886987B1/ko active IP Right Grant
- 2011-09-16 BR BR112013007022-6A patent/BR112013007022B1/pt active IP Right Grant
- 2011-09-16 ES ES11767661T patent/ES2704688T3/es active Active
- 2011-09-16 RU RU2013113965/15A patent/RU2580890C2/ru active
- 2011-09-22 US US13/239,903 patent/US20120082727A1/en not_active Abandoned
- 2011-09-29 AR ARP110103586A patent/AR083208A1/es not_active Application Discontinuation
-
2014
- 2014-01-29 HK HK14100919.2A patent/HK1187822A1/xx unknown
-
2015
- 2015-07-17 US US14/801,882 patent/US20150320691A1/en not_active Abandoned
-
2018
- 2018-01-12 US US15/869,162 patent/US20180133161A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
ES2704688T3 (es) | 2019-03-19 |
RU2013113965A (ru) | 2014-10-10 |
BR112013007022A2 (pt) | 2016-06-14 |
HK1187822A1 (en) | 2014-04-17 |
CA2813096A1 (en) | 2012-04-05 |
WO2012041717A1 (en) | 2012-04-05 |
CN103298470A (zh) | 2013-09-11 |
KR20170118231A (ko) | 2017-10-24 |
EP2621494A1 (en) | 2013-08-07 |
KR101886987B1 (ko) | 2018-08-08 |
US20120082727A1 (en) | 2012-04-05 |
US20150320691A1 (en) | 2015-11-12 |
CN103298470B (zh) | 2015-06-17 |
EP2621494B1 (en) | 2018-11-07 |
CA2813096C (en) | 2019-10-29 |
RU2580890C2 (ru) | 2016-04-10 |
PL2621494T3 (pl) | 2019-04-30 |
BR112013007022B1 (pt) | 2019-10-15 |
US20180133161A1 (en) | 2018-05-17 |
TR201901644T4 (tr) | 2019-02-21 |
KR20140005150A (ko) | 2014-01-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR083208A1 (es) | Uso de estearato de magnesio en formulaciones de polvo seco para inhalacion | |
CR20140365A (es) | Compuestos de carbamato y preparación y uso de los mismos | |
ECSP13012467A (es) | Uso de aglutinantes para fabricar formulaciones estables al almacenamiento | |
EP3216448B8 (en) | Parasiticidal oral veterinary compositions comprising systemically-acting active agents, methods and uses thereof | |
CL2013000677A1 (es) | Composicion farmaceutica en forma de tabletas que comprenden microgranulos gastrointestinales que contienen 100 a 800 mg de rifaximina, hasta 30% p/p de excipientes extragranulares y un recubrimiento formador de pelicula; y uso para tratar una enfermedad infecciosa y/o inflamatoria del intestino, tal como la enfermedad de crohn. | |
CL2014002283A1 (es) | Forma de dosificacion oral solida de liberacion inmediata que comprende particulas que comprenden un nucleo con un primer agente activo, un recubrimiento con un segundo agente activo sobre el y un material sensible al ph acido sobre dicho nucleo recubierto; proceso para prepararla; metodo de tratamiento; y uso para tratar dolor. | |
AR059350A1 (es) | Formulacion farmaceutica para aerosoles con dos o mas principios activos y al menos una sustancia tensioactiva | |
TR201900670T4 (tr) | İnhalasyon için yöntem ve formülasyon. | |
CY1120684T1 (el) | Σκευασμα ξηρης σκονης που περιλαμβανει ενα κορτικοστεροειδες και ενα βητα-αδρενεργικο για χορηγηση δια εισπνοης | |
PE20150668A1 (es) | Formulaciones farmaceuticas topicas no acuosas | |
WO2013114371A8 (en) | Dry powder formulations of dnase i | |
CO6640216A2 (es) | Composiciones farmacéuticas que comprenden hidromorfona y naloxona | |
WO2010021607A3 (en) | Pharmaceutical formulation | |
DOP2012000279A (es) | Composiciones farmaceuticas que comprenden hidromorfona y naloxona | |
UA103025C2 (ru) | Твердая композиция лекарственного средства замедленного высвобождения | |
EA201400737A1 (ru) | Система доставки на основе множества пеллет с немедленным высвобождением активного вещества | |
CO6640305A2 (es) | Elaboración de gránulos sin activos y tabletas que comprenden los mismos | |
DOP2014000269A (es) | Nueva dosificación y formulación | |
WO2013104892A8 (en) | Application of high dose compounds via inhalation | |
CL2015001748A1 (es) | Formulaciones antiparasitarias transdermicas | |
BR112013019924A2 (pt) | composições para cuidado oral | |
PH12015500374A1 (en) | Extended release compositions of an aminoalkyl nitrate | |
CL2016000182A1 (es) | Composición farmacéutica anti-tuberculosis estable en una forma de un comprimido recubierto que comprende gránulos de isoniazid y gránulos de rifapentina y su proceso de preparación | |
TR201009399A2 (tr) | Hızlı çözünen efervesan rosuvastatin formülasyonları. | |
CL2012002924A1 (es) | Una composicion que contiene como ingrediente activo a perclorato de 4-tioureido-iminometilpiridinio y sustancias farmaceuticamente aceptables; metodo de preparacion; y su uso para el tratamiento y/o la prevencion de todas las formas de tuberculosis pulmonar y extrapulmonar. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |